Evidence map›Paper›PMID 41155910›Full record

ArticlePharmaceutics2025

Leveraging the Immune Response from LIFE Biomaterial and Photon-Flash in Pre-Clinical Pancreatic Cancer Treatment.

Michele Moreau, Katelyn Kelly, Serena Mao, Debarghya China, Girmachew Wasihun, Aditya Pandya, MohammadAli Tajik-Mansoury, Daniel Sforza, Devin Miles, Amol K Narang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michele MoreauDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-6881-6300
Katelyn KellyDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Serena MaoDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Debarghya ChinaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0001-9053-8119
Girmachew WasihunDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0001-7785-9014
Aditya PandyaCenter for Molecular and Cellular Oncology, Yale School of Medicine, New Haven, CT 06511, USA.
MohammadAli Tajik-MansouryDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-9540-2672
Daniel SforzaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Devin MilesDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Amol K NarangDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Mohammad RezaeeDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Wilfred NgwaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
Kai DingDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-8202-0173

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapyR01CA239042 · NCI · JOHNS HOPKINS UNIVERSITY · PI NGWA, WILFRED · 2019 to 2023
$3.2M
An ultra-high (FLASH) dose rate x-ray cabinet system for pre-clinical laboratory radiation researchR01CA262097 · NCI · JOHNS HOPKINS UNIVERSITY · PI REZAEE, MOHAMMAD · 2021 to 2024
$2.1M
FLASH system funding 1R01CA262097-01NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA239042NCI NIH HHS R01 CA262097NIH HHS R01CA239042the Johns Hopkins Department of Radiation Oncology and Molecular Radiation Sciences Future Forward Award 80061570
6 · The paper itself

Abstract

Pre-clinical animal studies evaluating the 'flash effect' caused by ultra-high dose rate (≥40 Gy/s) favorably spares normal tissue from radiation-caused toxicity while maintaining anti-tumor effects like conventional (CONV) radiation. The goal of this study is to leverage an immune response resulting from the treatment combination of flash radiotherapy (Flash-RT) and LIFE (liquid immunogenic fiducial eluter) biomaterial incorporating an anti-mouse CD40 monoclonal antibody to enhance the therapeutic ratio in pancreatic cancer.

Indexed as

immune responseimmunohistochemistryLIFE Biomaterialradiotherapyultra-high dose rate (≥40 Gy/s) Flash

Identifiers

PMID41155910
PMCPMC12566649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.